This briefing assesses the inhumane conditions of female prisoners on death row, highlighting widespread violations of international agreements and standards.
This report reflects on the particular forms of discrimination facing women on death row, highlighting drug laws as a key driver for this inhumane form of punishment.
This briefing will present the latest trends and developments in these areas and discuss ways forward to uphold the human rights of people who use drugs.
This side event will be an opportunity to present the main findings of the report, as well as to discuss the report’s recommendations on the next decade in global drug policy.
In preparation for the 2019 High-Level Ministerial Segment of the UN Commission on Narcotic Drugs, the CSTF is launching an online global civil society consultation.
The Global Commission on Drug Policy analyses the global drug control regime's hindrances to the development agenda, and recommendations to end these frictions.
The INCB Watch is running a short series of posts to explore how the Board has changed – or remained the same – over the past decade or so. This post gives an overview of the areas we will analyse in the course of this project.
The International AIDS Society notes that, despite international agreements, enduring barriers hinder the access to HCV treatment by people who inject drugs.
The Institute for Criminal Policy Research at Birkbeck, University of London is holding a free international conference over two days, 8 and 9 November 2018, on the Bloomsbury campus.
The divergence between the Commission’s progressing stance on legal regulation and Trump’s Global Call to Action reminds us of the many obstacles facing drug policy reform. But it is also a promising reminder of the waning hegemony of the war on drugs rhetoric.
Far from an effort at achieving mutual understanding and genuine consensus on drug policy, the "Global Call to Action" is yet another instance of heavy-handed U.S. “with us or against us” diplomacy.
This advocacy note outlines key issues for consideration as member states reflect on what has been achieved since 2009, and the implications for the next phase of the international drug policy regime.
